Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top